8 research outputs found

    Recent Decisions

    Get PDF
    Comments on recent decisions by Robert R. Waterson, Hugh E. Wall, Francis W. Matthys, Granville P. Ziegler, Thomas H. Nelson, Stanley A. Rosenstein, and John M. Doyle

    Brain-behaviour modes of covariation in healthy and clinically depressed young people.

    Get PDF
    Understanding how variations in dimensions of psychometrics, IQ and demographics relate to changes in brain connectivity during the critical developmental period of adolescence and early adulthood is a major challenge. This has particular relevance for mental health disorders where a failure to understand these links might hinder the development of better diagnostic approaches and therapeutics. Here, we investigated this question in 306 adolescents and young adults (14-24 y, 25 clinically depressed) using a multivariate statistical framework, based on canonical correlation analysis (CCA). By linking individual functional brain connectivity profiles to self-report questionnaires, IQ and demographic data we identified two distinct modes of covariation. The first mode mapped onto an externalization/internalization axis and showed a strong association with sex. The second mode mapped onto a well-being/distress axis independent of sex. Interestingly, both modes showed an association with age. Crucially, the changes in functional brain connectivity associated with changes in these phenotypes showed marked developmental effects. The findings point to a role for the default mode, frontoparietal and limbic networks in psychopathology and depression.Wellcome Trus

    Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis

    Full text link

    Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies

    Get PDF

    Recent Decisions

    No full text
    Comments on recent decisions by Robert R. Waterson, Hugh E. Wall, Francis W. Matthys, Granville P. Ziegler, Thomas H. Nelson, Stanley A. Rosenstein, and John M. Doyle

    Recent Decisions

    No full text
    Comments on recent decisions by Robert R. Waterson, Hugh E. Wall, Francis W. Matthys, Granville P. Ziegler, Thomas H. Nelson, Stanley A. Rosenstein, and John M. Doyle

    Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis

    Get PDF
    Lung cancer is a leading cause of cancer-related deaths worldwide. Lung cancer risk factors, including smoking and exposure to environmental carcinogens, have been linked to chronic inflammation. An integral feature of inflammation is the activation, expansion and infiltration of diverse immune cell types, including CD4+ T cells. Within this T cell subset are immunosuppressive regulatory T (Treg) cells and pro-inflammatory T helper 17 (Th17) cells that act in a fine balance to regulate appropriate adaptive immune responses. In the context of lung cancer, evidence suggests that Tregs promote metastasis and metastatic tumor foci development. Additionally, Th17 cells have been shown to be an integral component of the inflammatory milieu in the tumor microenvironment, and potentially involved in promoting distinct lung tumor phenotypes. Studies have shown that the composition of Tregs and Th17 cells are altered in the tumor microenvironment, and that these two CD4+ T cell subsets play active roles in promoting lung cancer progression and metastasis. We review current knowledge on the influence of Treg and Th17 cells on lung cancer tumorigenesis, progression, metastasis and prognosis. Furthermore, we discuss the potential biological and clinical implications of the balance among Treg/Th17 cells in the context of the lung tumor microenvironment and highlight the potential prognostic function and relationship to metastasis in lung cancer.Medicine, Faculty ofScience, Faculty ofNon UBCMicrobiology and Immunology, Department ofPathology and Laboratory Medicine, Department ofZoology, Department ofReviewedFacult

    Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies

    Get PDF
    Photodynamic therapy (PDT) has emerged as a promising alternative to conventional cancer therapies such as surgery, chemotherapy, and radiotherapy. PDT comprises the administration of a photosensitizer, its accumulation in tumor tissue, and subsequent irradiation of the photosensitizer-loaded tumor, leading to the localized photoproduction of reactive oxygen species (ROS). The resulting oxidative damage ultimately culminates in tumor cell death, vascular shutdown, induction of an antitumor immune response, and the consequent destruction of the tumor. However, the ROS produced by PDT also triggers a stress response that, as part of a cell survival mechanism, helps cancer cells to cope with the PDT-induced oxidative stress and cell damage. These survival pathways are mediated by the transcription factors activator protein 1 (AP-1), nuclear factor E2-related factor 2 (NRF2), hypoxia-inducible factor 1 (HIF-1), nuclear factor ÎşB (NF-ÎşB), and those that mediate the proteotoxic stress response. The survival pathways are believed to render some types of cancer recalcitrant to PDT and alter the tumor microenvironment in favor of tumor survival. In this review, the molecular mechanisms are elucidated that occur post-PDT to mediate cancer cell survival, on the basis of which pharmacological interventions are proposed. Specifically, pharmaceutical inhibitors of the molecular regulators of each survival pathway are addressed. The ultimate aim is to facilitate the development of adjuvant intervention strategies to improve PDT efficacy in recalcitrant solid tumors
    corecore